AstraZeneca & Merck Group

AstraZeneca: AstraZeneca is the central company, facing another pipeline setback with the discontinuation of the volrustomig trial. Despite this, it reported positive results from other trials and reaffirmed its 2030 revenue target, with shares rising slightly.

Merck Group: Merck's Keytruda is the comparator in the trial, and the failure of volrustomig may reinforce the competitive position of Keytruda in lung cancer treatment.

AstraZeneca: Technology from its COVID-19 vaccine is used in the Oxford Ebola vaccine, indirectly involved.

Merck Group: Merck Group's Ervebo vaccine is being deployed in the outbreak response, potentially increasing sales. However, its efficacy against the Bundibugyo strain is unproven, and the trial outcome will be critical.

AstraZeneca: Its COVID-19 vaccine technology is used in the Oxford candidate, but AstraZeneca itself is not directly involved in the Ebola response.

Merck Group: Manufacturer of RVSV-ZEBOV vaccine, which is being considered for cross-protection trials. Its vaccine could play a role in the response, benefiting its reputation.

AstraZeneca: AstraZeneca is a partner of Ascentage Pharma, but this event does not directly involve AstraZeneca.

Merck Group: Merck is a partner of Ascentage Pharma, but this event does not directly involve Merck.